Komori
Share Issuance and Disposal4884Kringle Pharma,Inc.Pharmaceuticals

Supplementary Information on Financing

Describes the overview, purpose, use of proceeds and estimated amount to be raised through financing combining a third-party allotment of shares with the issuance of stock acquisition rights. This is not a document correcting the existing disclosure.

Worth reading
—
Scored from 0 of 3 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Avoiding a definitive answer
How definitive the wording is.

What was corrected and how

A subsequent correction by the company to the contents of an already published filing.

Original disclosure
The number of days elapsed cannot be calculated because the original disclosure date is unknown.
This correction2026-11-11
Impact on Business Performance (the company’s explanation)

The impact of the issuance of these stock acquisition rights on results for the current fiscal year will be immaterial. If the issuance affects future results, the company plans to make timely disclosure as appropriate.

What was corrected and how
ItemDetails
Impact on Business PerformanceThe impact of the issuance of these stock acquisition rights on results for the current fiscal year will be immaterial. If the issuance affects future results, the company plans to make timely disclosure as appropriate.
Items this document does not state (5)
Disclosure subject to correctionOriginal disclosure dateLocation of correctionDetails of correctionReason for correction

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The stated purposes of the financing are preparation for a Phase III clinical trial for acute spinal cord injury in the United States, establishment of a manufacturing system for HGF active pharmaceutical ingredient using a new manufacturing method, securing domestic active pharmaceutical ingredient inventories and funding working capital.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Supplementary Information on Financing | Kringle Pharma,Inc. (4884) timely disclosure | Komori